Literature DB >> 8068

Clinical studies of induction agents XLIII: Flunitrazepam.

J W Dundee, C R Varadarajan, J H Gaston, R S Clarke.   

Abstract

Flunitrazepam (Ro 5-4200) has been studied as an induction agent in 220 volunteers or patients. It was assumed to be 10 times as potent as diazepam. The maximum soporific effect did not occur until 90-120 s after injection. There was great individual variation in response to flunitrazepam and some patients did not lose consciousness even after receiving 6 mg (approximately 0.1 mg/kg). Opiate premedication enhanced its action, but delayed recovery. There was a dose-related increase in minor respiratory upset with flunitrazepam in unpremedicated patients and a high frequency of arterial hypotension following large doses given to patients who had received opiate premedication. Venous sequelae were no more frequent than after comparable doses of diazepam. Flunitrazepam was not a very satisfactory drug for the induction of anaesthesia, and recovery was too prolonged for routine use.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8068     DOI: 10.1093/bja/48.6.551

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Comparison of flunitrazepam and thiopentone for induction of general anaesthesia.

Authors:  J R Maltby; R C Hamilton; R Phillips
Journal:  Can Anaesth Soc J       Date:  1980-07

Review 2.  Flunitrazepam: a review of its pharmacological properties and therapeutic use.

Authors:  M A Mattila; H M Larni
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

Review 3.  Midazolam. A review of its pharmacological properties and therapeutic use.

Authors:  J W Dundee; N J Halliday; K W Harper; R N Brogden
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

4.  Effect of flunitrazepam as an oral hypnotic on 24-hour blood pressure in healthy volunteers.

Authors:  Daniele Bosone; Roberto Fogari; Annalisa Zoppi; Angela D'Angelo; Natascia Ghiotto; Giulia Perini; Matteo Cotta Ramusino; Alfredo Costa
Journal:  Eur J Clin Pharmacol       Date:  2018-04-30       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.